B, B, H, & B Inc’s AbbVie ABBV Stock Holding History

B, B, H, & B Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-114	Closed	-$12K	–	31
2020 Q4	$12K	Buy	+114	New	+$11K	0.01%	106

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

B, B, H, & B Inc's ABBV Position: Q1 2021 in Review

B, B, H, & B Inc sold out of AbbVie (ABBV) in Q1 2021, closing a stake of 114 shares — an estimated $12K sold.

B, B, H, & B Inc first reported a position in ABBV in Q4 2020 and held it in 1 quarter. The position peaked at $12K in Q4 2020. 2,614 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

B, B, H, & B Inc reported no remaining AbbVie position as of Q1 2021 after selling out during the quarter.
B, B, H, & B Inc sold 114 AbbVie shares in Q1 2021, an estimated $12K.
B, B, H, & B Inc first reported a position in AbbVie in Q4 2020 and held it in 1 quarter.
B, B, H, & B Inc's AbbVie position peaked at $12K in Q4 2020.
2,614 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on B, B, H, & B Inc's 13F filing for Q1 2021, filed 11 May 2021.